Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
Status:
Recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that, in newly diagnosed de novo chronic phase CML patients, an
induction treatment with ponatinib for 6 months should increase the rate of patients reaching
a stable MR4.5 allowing cessation of imatinib treatment.
The investigators proposal is to conduct a multicenter, Phase II trial to evaluate the
safety, clinical and biological activity of an induction treatment with ponatinib for 6
months, followed by a consolidation treatment with imatinib in newly diagnosed de novo
chronic phase CML patients.